BeBetter Med

BeBetter Medicine gains FDA approval to begin clinical trials for **BEBT-701**, a first-in-class therapy targeting both hypertension and elevated LDL-C. The drug represents the company’s first investigational new drug entering human testing, focusing on mild-to-moderate hypertension with high cholesterol. This marks a potential advancement in dual-target cardiovascular treatments.

Apr 2026Insight, China's Pharmaceutical IndustryNews article

BeBetter Medicine secures NMPA approval to test ifupinostat (BEBT-908), a dual HDAC/PI3Kα inhibitor, in combination with CHOP chemotherapy for newly diagnosed peripheral T-cell lymphoma (PTCL). The drug, already conditionally approved for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), now enters first-line T-cell lymphoma treatment. This marks the first HDAC/PI3Kα dual inhibitor in a Phase I/II study for frontline PTCL patients.

Mar 2026Insight, China's Pharmaceutical IndustryNews article

Guangzhou BeBetter Medicine Technology secures NMPA approval for a Phase I/II trial of **BEBT-701**, a first-in-class siRNA therapy targeting hypertension and elevated LDL-C. The drug combines AGT and PCSK9 inhibition using the company’s proprietary **GalNAc dual oligonucleotide conjugate (GDOC)** platform. The trial will enroll patients with mild-to-moderate hypertension.

Feb 2026Insight, China's Pharmaceutical IndustryNews article

Guangzhou BeBetter Medicine Co., Ltd. secures conditional approval from China’s National Medical Products Administration (NMPA) for **Ifupinostat Hydrochloride for Injection (Beitelin)**, a treatment for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The drug represents a new therapeutic option in China for patients with this aggressive blood cancer. Beitelin targets epigenetic regulation to potentially improve outcomes in advanced-stage cases.

Nov 2025DengYueMedNews article